Of Life and Limb: Addition of Low-Dose Rivaroxaban for Secondary Prevention After Peripheral Artery Disease Surgery

Elizabeth L George¹, Shipra Arya^{1

2}

Affiliations

¹ Division of Vascular Surgery, Department of Surgery, Stanford University School of Medicine, CA (E.L.G., S.A.).
² Surgery Service Line, VA Palo Alto Healthcare System, CA (S.A.).

Editorial

Elizabeth L George et al. Circulation. 2021.

. 2021 Oct 5;144(14):1117-1119.

doi: 10.1161/CIRCULATIONAHA.121.056291. Epub 2021 Oct 4.

Elizabeth L George¹, Shipra Arya^{1

2}

¹ Division of Vascular Surgery, Department of Surgery, Stanford University School of Medicine, CA (E.L.G., S.A.).
² Surgery Service Line, VA Palo Alto Healthcare System, CA (S.A.).

No abstract available

Keywords: Editorials; peripheral artery disease; rivaroxaban.

Comment on

Effect of Rivaroxaban and Aspirin in Patients With Peripheral Artery Disease Undergoing Surgical Revascularization: Insights From the VOYAGER PAD Trial.
Debus ES, Nehler MR, Govsyeyev N, Bauersachs RM, Anand SS, Patel MR, Fanelli F, Capell WH, Brackin T, Hinterreiter F, Krievins D, Nault P, Piffaretti G, Svetlikov A, Jaeger N, Hess CN, Sillesen HH, Conte M, Mills J, Muehlhofer E, Haskell LP, Berkowitz SD, Hiatt WR, Bonaca MP. Debus ES, et al. Circulation. 2021 Oct 5;144(14):1104-1116. doi: 10.1161/CIRCULATIONAHA.121.054835. Epub 2021 Aug 12. Circulation. 2021. PMID: 34380322 Clinical Trial.